ACM
BMY icon

Anfield Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Anfield Capital Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.64K Sell
93
-250
-73% -$14.6K ﹤0.01% 496
2025
Q4 		$18.5K Hold
343
– – 0.01% 271
2025
Q3 		$15.5K Buy
343
+258
+304% +$12K ﹤0.01% 277
2025
Q2 		$3.94K Hold
85
– – ﹤0.01% 392
2025
Q1 		$5.18K Hold
85
– – ﹤0.01% 318
2024
Q4 		$4.81K Sell
85
-75
-47% -$4.19K ﹤0.01% 319
2024
Q3 		$8.28K Buy
160
+75
+88% +$3.52K ﹤0.01% 257
2024
Q2 		$3.53K Buy
+85
New +$3.8K ﹤0.01% 292
2020
Q1 		– Sell
-100
Closed -$7K – 143
2019
Q4 		$7K Buy
+100
New +$5.73K ﹤0.01% 346

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Anfield Capital Management's BMY Position: Q1 2026 in Review

Anfield Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 73% in Q1 2026, selling an estimated $14.6K and leaving 93 shares worth $5.64K. The position accounts for ﹤0.01% of the portfolio, ranked #496.

Anfield Capital Management first reported a position in BMY in Q4 2019 and has held it in 9 quarters since. The position peaked at $18.5K in Q4 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Anfield Capital Management held 93 shares of Bristol-Myers Squibb worth $5.64K as of Q1 2026.
  • Anfield Capital Management sold 250 Bristol-Myers Squibb shares in Q1 2026, an estimated $14.6K.
  • Bristol-Myers Squibb made up ﹤0.01% of Anfield Capital Management's portfolio in Q1 2026, its #496 holding.
  • Anfield Capital Management first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 9 quarters since.
  • Anfield Capital Management's Bristol-Myers Squibb position peaked at $18.5K in Q4 2025.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Anfield Capital Management's 13F filing for Q1 2026, filed 12 May 2026.